Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.
According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.
However, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。